0 0.5 1 1.5+ All studies 38% 20 37,785 Improvement, Studies, Patients Relative Risk Mortality 43% 9 4,976 Ventilation 18% 2 2,249 Hospitalization 26% 12 6,712 Progression 35% 9 4,850 Recovery 49% 4 2,368 Cases 27% 2 9,116 Viral clearance -25% 2 1,003 RCTs 31% 9 5,964 RCT mortality 27% 2 2,973 Prophylaxis 27% 5 29,766 Early 43% 11 4,929 Late 48% 4 3,090 Fluvoxamine for COVID-19 c19early.org October 2023 Favorsfluvoxamine Favorscontrol